Home » Stocks » PCVX

Vaxcyte, Inc. (PCVX)

Stock Price: $23.56 USD -1.64 (-6.51%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $23.70 +0.14 (0.59%) Feb 26, 7:12 PM
Market Cap 1.20B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 50.90M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $23.56
Previous Close $25.20
Change ($) -1.64
Change (%) -6.51%
Day's Open 25.23
Day's Range 23.07 - 25.53
Day's Volume 456,061
52-Week Range 17.80 - 58.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

FOSTER CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to p...

Seeking Alpha - 2 months ago

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

Other stocks mentioned: ABNB, AI, AZEK, DASH, GBIO, RNA, UCL, VRM
GlobeNewsWire - 3 months ago

FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and ...

GlobeNewsWire - 3 months ago

FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and ...

GlobeNewsWire - 3 months ago

FOSTER CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and ...

GlobeNewsWire - 5 months ago

FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior a...

GlobeNewsWire - 6 months ago

FOSTER CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Vaxcyte, Inc. (Nasdaq: PCVX), please note that in the first bullet under “...

GlobeNewsWire - 6 months ago

FOSTER CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior an...

CNN Business - 8 months ago

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...

Other stocks mentioned: BIO, FMTX, IMRA, KROS, RNA, RPTX, XBI, ZNTL
GlobeNewsWire - 8 months ago

FOSTER CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vacci...

Market Watch - 8 months ago

Shares of Vaxcyte Inc. soared 22% in their trading debut Friday, after the company's IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to ...

Market Watch - 8 months ago

Vaxcyte Inc. priced its initial public offering late Thursday at $16 a share, the top end of its price range, and upzied the deal to 15.6 million shares from earlier plans to sell just 14 mil...

About PCVX

Vaxcyte, a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The com... [Read more...]

Industry
Biotechnology
IPO Date
Jun 12, 2020
CEO
Grant Pickering
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
PCVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Vaxcyte stock is "Strong Buy." The 12-month stock price forecast is 49.75, which is an increase of 111.16% from the latest price.

Price Target
$49.75
(111.16% upside)
Analyst Consensus: Strong Buy